Modulation of gut-associated lymphoid tissue functions with genetically modified lactococcus lactis

International Reviews of Immunology

Volumn 28, Issue 6, 2009, Pages 465-486

  Rottiers, Pieter ^a   De Smedt, Tim ^a   Steidler, Lothar ^a  

^a ActoGeniX NV   (Belgium)

Author keywords

Biotechnology; Gut associated lymphoid tissue; Immunomodulation; Lactococcus

Indexed keywords

INTERLEUKIN 10; TREFOIL PEPTIDE;

CHEESE; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; ENTERITIS; FOOD ALLERGY; GENETIC ENGINEERING; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INTESTINE LYMPHATIC TISSUE; LACTIC ACID BACTERIUM; LACTOCOCCUS LACTIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; TRANSGENIC ORGANISM;

ANIMALS; DRUG EVALUATION, PRECLINICAL; GASTROINTESTINAL TRACT; GENETIC ENGINEERING; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-10; LACTOCOCCUS LACTIS; LYMPHOID TISSUE; PEPTIDES;

EID: 71449127101     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830180903197498     Document Type: Review

References (90)

1. D. Taupin and D.K. Podolsky. Trefoil factors: Initiators of mucosal healing. Nat Rev Mol Cell Biol 4: 721-732, 2003.
2. M.T. Abreu-Martin and S.R. Targan. Regulation of immune responses of the intestinal mucosa. Crit Rev Immunol 16: 277-309, 1996.
3. M.C. Noverr and G.B. Huffnagle. Does the microbiota regulate immune responses outside the gut? Trends Microbiol 12: 562-568, 2004.
4. D. Kelly, J.I. Campbell, T.P. King, et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol 5: 104-112, 2004.
5. A.J. Macpherson and N.L. Harris. Interactions between commensal intestinal bacteria and the immune system. Nat Rev Immunol 4: 478-485, 2004.
6. Probiotics or con (editorial)? Lancet 371: 624, 2008.
7. R.N. Fedorak and L.A. Dieleman. Probiotics in the treatment of human inflammatory bowel diseases: Update 2008. J Clin Gastroenterol 42(Suppl 2): S97-S103, 2008.
8. S. Salminen and A. von Wright. Current Probiotics-Safety Assured? Microb Ecol Health Dis 10: 68-77, 1998.
9. L. Steidler. Genetically engineered probiotics. Best Pract Res Clin Gastroenterol 17: 861-876, 2003.
10. K.F. Schleifer. Recent changes in the taxonomy of lactic-acid bacteria. Fems Microbiology Reviews 46: 201-203, 1987.
11. K.H. Schleifer, J. Kraus, C. Dvorak, et al. Transfer of Streptococcus-Lactis and related Streptococci to the genus Lactococcus Gen-Nov. Syst Appl Microbiol 6: 183-195, 1985.
12. EFSA. Opinion of the Scientific Committee on a request from EFSA related to 'A generic approach to the safety assessment by EFSA of micro-organisms used in food/feed and the production of food/feed additives'. EFSA J 226: 1-12, 2005.
13. EFSA. Annex 3: Assessment of Gram-positive, non-sporulating bacteria with respect to a qualified presumption of safety. 2007.
14. M. Gruzza, M. Fons, M.F. Ouriet, et al. Study of gene transfer in vitro and in the digestive tract of gnotobiotic mice from Lactococcus lactis strains to various strains belonging to human intestinal flora. Microb Releases 2: 183-189, 1994.
15. S. Drouault,G. Corthier, S.D. Ehrlich, and P. Renault. Survival, physiology, and lysis of Lactococcus lactis in the digestive tract. Appl Environ Microbiol 65: 4881-4886, 1999.
16. J.M. Wells, P.W. Wilson, and R.W. Le Page. Improved cloning vectors and transformation procedure for Lactococcus lactis. J Appl Bacteriol 74: 629-636, 1993.
17. F.E. Ahmed. Genetically modified probiotics in foods. Trends Biotechnol 21: 491-497, 2003.
18. M. Kleerebezem and J. Hugenholtz. Metabolic pathway engineering in lactic acid bacteria. Curr Opin Biotechnol 14: 232-237, 2003.
19. A. Bolotin, P. Wincker, S. Mauger, et al. The complete genome sequence of the lactic acid bacterium Lactococcus lactis ssp. lactis IL1403. Genome Res 11: 731-753, 2001.
20. U.Wegmann, M. O'Connell-Motherway, A. Zomer, et al. Complete genome sequence of the prototype lactic acid bacterium Lactococcus lactis subsp. cremoris MG1363. J Bacteriol 189: 3256-3270, 2007.
21. M. van Asseldonk, G. Rutten, M. Oteman, et al. Cloning of usp45, a gene encoding a secreted protein from Lactococcus lactis subsp. lactis MG1363. Gene 95: 155-160, 1990.
22. S.J. Lee, D.M. Kim, K.H. Bae, et al. Enhancement of secretion and extracellular stability of staphylokinase in Bacillus subtilis by wprA gene disruption. Appl Environ Microbiol 66: 476-480, 2000.
23. X.C.Wu,W. Lee, L. Tran, and S.L.Wong. Engineering a Bacillus subtilis expressionsecretion system with a strain deficient in six extracellular proteases. J Bacteriol 173: 4952-4958, 1991.
24. V. Enouf, P. Langella, J. Commissaire, et al. Bovine rotavirus nonstructural protein 4 produced by Lactococcus lactis is antigenic and immunogenic. Appl Environ Microbiol 67: 1423-1428, 2001.
25. P. Ravn, J. Arnau, S.M. Madsen, et al. The development of TnNuc and its use for the isolation of novel secretion signals in Lactococcus lactis. Gene 242: 347-356, 2000.
26. L. Steidler, S. Neirynck,N. Huyghebaert, et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol 21: 785-789, 2003.
27. F. Bringel, G.L. Van Alstine, and J.R. Scott. A host factor absent from Lactococcus lactis subspecies lactis MG1363 is required for conjugative transposition. Mol Microbiol 5: 2983-2993, 1991.
28. M.B. Pedersen, P.R. Jensen, T. Janzen, and D. Nilsson. Bacteriophage resistance of a deltathyA mutant of Lactococcus lactis blocked in DNA replication. Appl Environ Microbiol 68: 3010-3023, 2002.
29. C.M. Thomas and K.M. Nielsen. Mechanisms of, and barriers to, horizontal gene transfer between bacteria. Nat Rev Microbiol 3: 711-721, 2005.
30. J.G. Lawrence. Gene transfer, speciation, and the evolution of bacterial genomes. Curr Opin Microbiol 2: 519-523, 1999.
31. H. Ochman, J.G. Lawrence, and E.A. Groisman. Lateral gene transfer and the nature of bacterial innovation. Nature 405: 299-304, 2000.
32. M.J. Gasson. Plasmid complements of Streptococcus lactis NCDO 712 and other lactic streptococci after protoplast-induced curing. J Bacteriol 154: 1-9, 1983.
33. L. Schotte, L. Steidler, J. Vandekerckhove, and E. Remaut. Secretion of biologically active murine interleukin-10 by Lactococcus lactis. Enzyme Microb Technol 27: 761-765, 2000.
34. L. Steidler, W. Hans, L. Schotte, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289: 1352-1355, 2000.
35. L. Steidler, K. Robinson, L. Chamberlain, et al. Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis coexpressing antigen and cytokine. Infect Immun 66: 3183-3189, 1998.
36. L. Steidler, J.M.Wells, A. Raeymaekers, et al. Secretion of biologically active murine interleukin-2 by Lactococcus lactis subsp. lactis. Appl Environ Microbiol 61: 1627-1629, 1995.
37. L.G. Bermudez-Humaran, P. Langella, N.G. Cortes-Perez, et al. Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production. Infect Immun 71: 1887-1896, 2003.
38. R. Kuhn, J. Lohler, D. Rennick, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263-274, 1993.
39. R.N. Fedorak, A. Gangl, C.O. Elson, et al. Recombinant human interleukin 10 in the treatment of patients withmild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 119: 1473-1482, 2000. (Pubitemid 32198672)
40. S. Schreiber, R.N. Fedorak, O.H. Nielsen, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology 119: 1461-1472, 2000. (Pubitemid 32198671)
41. S. Schreiber, R.N. Fedorak, G.Wild, et al. Safety and tolerance of rhIL-10 treatment in patients withmild/moderate active ulcerative colitis. Gastroenterology 114: 1080, 1998.
42. H. Herfarth and J. Scholmerich. IL-10 therapy in Crohn's disease: At the crossroads. Treatment of Crohn's disease with the anti-inflammatory cytokine interleukin 10. Gut 50: 146-147, 2002.
43. K. Madsen. Combining T cells and IL-10: A new therapy for Crohn's disease? Gastroenterology 123: 2140-2144, 2002.
44. L. Schotte, L. Steidler, J. Vandekerckhove, and E. Remaut. Secretion of biologically active murine interleukin-10 by Lactococcus lactis. Enzyme and Microb Technol 27: 761-765, 2000.
45. N. Huyghebaert, A. Vermeire, S. Neirynck, et al. Development of an enteric-coated formulation containing freeze-dried, viable recombinant Lactococcus lactis for the ileal mucosal delivery of human interleukin-10. Euro J Pharma Biopharma 60: 349-359, 2005. (Pubitemid 40922832)
46. B. Foligne, S. Nutten, L. Steidler, et al. Recommendations for improved use of the murine TNBS-induced colitis model in evaluating anti-inflammatory properties of lactic acid bacteria: Technical and microbiological aspects. Dig Dis Sci 51: 390-400, 2006.
47. S. Termont, K. Vandenbroucke, D. Iserentant, et al. Intracellular accumulation of trehalose protects Lactococcus lactis from freeze-drying damage and bile toxicity and increases gastric acid resistance. Appl Env Microb 72: 7694-7700, 2006.
48. B. Foligne, R. Dessein, M. Marceau, et al. Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein. Gastroenterology 133: 862-874, 2007.
49. H. Braat, P. Rottiers, D.W. Hommes, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 4: 754-759, 2006.
50. B. Kleessen, A.J. Kroesen, H.J. Buhr, and M. Blaut. Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls. Scand J Gastroenterol 37: 1034-1041, 2002.
51. A. Waeytens, L. Ferdinande, S. Neirynck, et al. Paracellular entry of interleukin-10 producing Lactococcus lactis in inflamed intestinal mucosa in mice. Inflamm Bowel Dis 14: 471-479, 2007.
52. A.V.Keita, E. Gullberg, A.C. Ericson, et al. Characterization of antigen and bacterial transport in the follicle-associated epithelium of human ileum. Lab Invest 86: 504-516, 2006.
53. M. Rescigno, M. Urbano, B. Valzasina, et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol 2: 361-367, 2001.
54. M. Rescigno, G. Rotta, B. Valzasina, and P. Ricciardi-Castagnoli. Dendritic cells shuttle microbes across gut epithelial monolayers. Immunobiology 204: 572-581, 2001.
55. H.A. Sampson. Food allergy. Part 2: Diagnosis and management. J Allergy Clin Immunol 103: 981-989, 1999.
56. H.A. Sampson. Food allergy. Part 1: Immunopathogenesis and clinical disorders. J Allergy Clin Immunol 103: 717-728, 1999.
57. C.P. Frossard, C. Hauser, and P.A. Eigenmann. Antigen-specific secretory IgA antibodies in the gut are decreased in a mouse model of food allergy. J Allergy Clin Immunol 114: 377-382, 2004.
58. C.P. Frossard, L. Tropia, C. Hauser, and P.A. Eigenmann. Lymphocytes in Peyer patches regulate clinical tolerance in a murine model of food allergy. J Allergy Clin Immunol 113: 958-964, 2004.
59. C.P. Frossard, L. Steidler, and P.A. Eigenmann. Oral administration of an IL-10- secreting Lactococcus lactis strain prevents food-induced IgE sensitization. J Allergy Clin Immunol 119: 952-959, 2007.
60. T. Marchbank, B.R. Westley, F.E. May, et al. Dimerization of human pS2 (TFF1) plays a key role in its protective/healing effects. J Pathol 185: 153-158, 1998.
61. R.J. Playford, T. Marchbank, R.A. Goodlad, et al. Transgenic mice that overexpress the human trefoil peptide pS2 have an increased resistance to intestinal damage. Proc Natl Acad Sci U S A 93: 2137-2142, 1996.
62. R.J. Playford, T. Marchbank, R. Chinery, et al. Human spasmolytic polypeptide is a cytoprotective agent that stimulates cell migration. Gastroenterology 108: 108-116, 1995.
63. P.C. Konturek, T. Brzozowski, S.J. Konturek, et al. Role of spasmolytic polypeptide in healing of stress-induced gastric lesions in rats. Regul Pept 68: 71-79, 1997.
64. C. McKenzie, T.Marchbank, R.J. Playford, et al. Pancreatic spasmolytic polypeptide protects the gastric mucosa but does not inhibit acid secretion or motility. Am J Physiol 273: G112-G117, 1997.
65. S.S. Poulsen, J. Thulesen, L. Christensen, et al. Metabolism of oral trefoil factor 2 (TFF2) and the effect of oral and parenteral TFF2 on gastric and duodenal ulcer healing in the rat. Gut 45: 516-522, 1999.
66. M.W. Babyatsky, M. deBeaumont, L. Thim, and D.K. Podolsky. Oral trefoil peptides protect against ethanol- and indomethacin-induced gastric injury in rats. Gastroenterology 110: 489-497, 1996.
67. G.A. Cook, L. Thim, N.D. Yeomans, and A.S. Giraud. Oral human spasmolytic polypeptide protects against aspirin-induced gastric injury in rats. J Gastroenterol Hepatol 13: 363-370, 1998.
68. C.P. Tran, G.A. Cook, N.D. Yeomans, et al. Trefoil peptide TFF2 (spasmolytic polypeptide) potently accelerates healing and reduces inflammation in a rat model of colitis. Gut 44: 636-642, 1999.
69. R. Chinery and R.J. Playford. Combined intestinal trefoil factor and epidermal growth factor is prophylactic against indomethacin-induced gastric damage in the rat. Clin Sci (Lond) 88: 401-403, 1995.
70. B.H. Zhang,H.G. Yu, Z.X. Sheng, et al. The therapeutic effect of recombinant human trefoil factor 3 on hypoxia-induced necrotizing enterocolitis in immature rat. Regul Pept 116: 53-60, 2003.
71. P.L. Beck, J.F. Wong, Y. Li, et al. Chemotherapy- and radiotherapy-induced intestinal damage is regulated by intestinal trefoil factor. Gastroenterology 126: 796-808, 2004.
72. K. Vandenbroucke, W. Hans, J. Van Huysse, et al. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology 127: 502-513, 2004.
73. M. Miyara and S. Sakaguchi. Natural regulatory T cells: Mechanisms of suppression. Trends Mol Med 13: 108-116, 2007.
74. I.L. Huibregtse, V. Snoeck, A. de Creus, et al. Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin. Gastroenterology 133: 517-528, 2007.
75. A.M. Faria and H.L. Weiner. Oral tolerance. Immunol Rev 206: 232-259, 2005.
76. T.A. Kraus and L. Mayer. Oral tolerance and inflammatory bowel disease. Curr Opin Gastroenterol 21: 692-696, 2005.
77. H.L. Weiner. Current issues in the treatment of human diseases by mucosal tolerance. Ann N Y Acad Sci 1029: 211-224, 2004.
78. A. Friedman and H.L. Weiner. Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc Natl Acad Sci U S A 91: 6688-6692, 1994.
79. A.M. Mowat, S. Strobel, H.E. Drummond, and A. Ferguson. Immunological responses to fed protein antigens in mice. I. Reversal of oral tolerance to ovalbumin by cyclophosphamide. Immunology 45: 105-113, 1982.
80. T. Yoshida, S. Hachimura, and S. Kaminogawa. The oral administration of low-dose antigen induces activation followed by tolerization, while high-dose antigen induces tolerance without activation. Clin Immunol Immunopathol 82: 207-215, 1997.
81. I. Huibrechtse, E. Marietta, S. Rashtak, et al. Induction of antigen-specific tolerance by oral administration of Lactococcus lactis-delivered immunodominant DQ8- restricted Gliadin peptide in sensitized NOD ABo DQ8 transgenic mice. J Immunol 183: 2390-2396, 2009.
82. W.M. de Vos. Gene expression systems for lactic acid bacteria. Curr Opin Microbiol 2: 289-295, 1999.
83. Y. Dieye, S. Usai, F. Clier, et al. Design of a protein-targeting system for lactic acid bacteria. J Bacteriol 183: 4157-4166, 2001.
84. Y. Le Loir, V. Azevedo, S.C. Oliveira, et al. Protein secretion in Lactococcus lactis: An efficient way to increase the overall heterologous protein production. Microb Cell Fact 4: 2, 2005.
85. A.M. Dose. The symptom experience of mucositis, stomatitis, and xerostomia. Semin Oncol Nurs 11: 248-255, 1995.
86. S. Bruce and A. Quinn. The pain of oral mucositis. US Oncological Disease: Cancer- Related Complications; Touch Briefings 1: 86-90, 2007.
87. L.E. Volpato, T.C. Silva, T.M. Oliveira, et al. Radiation therapy and chemotherapyinduced oral mucositis. Rev Bras Otorrinolaringol (Engl Ed) 73: 562-568, 2007.
88. P. Rottiers, S. Caluwaerts, L. Steidler, et al. Effect of amouth rinse formulation with human trefoil factor 1-secreting Lactococcus lactis in experimental oral mucositis in hamsters. Support Care Cancer 17: 857-1039 [1010-1092], 2009.
89. K. Vandenbroucke, L. Huyck, P. Demetter, et al. Treatment of murine colitis by Lactococcus lactis secreting anti-tumor necrosis factor NanobodiesTM. 4th Annual Broad Medical Research Program Investigator Meeting for Inflammatory Bowel Disease: Abstract. 2006.
90. A.B. Kay. Allergy and allergic diseases. (First of two parts.) N Engl J Med 344: 30-37, 2001.